Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 11th. The shares were sold at an average price of $279.74, for a total transaction of $2,797,400.00. Following the completion of the sale, the director now directly owns 14,300 shares of the company’s stock, valued at approximately $4,000,282. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of MASI stock opened at $276.27 on Thursday. The stock has a market cap of $15.21 billion, a P/E ratio of 71.76, a P/E/G ratio of 3.90 and a beta of 0.87. The company has a fifty day moving average price of $266.33 and a two-hundred day moving average price of $238.93. Masimo Co. has a one year low of $143.90 and a one year high of $284.86.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Saturday, October 31st. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.18. The firm had revenue of $278.11 million during the quarter, compared to analysts’ expectations of $275.00 million. Masimo had a net margin of 20.30% and a return on equity of 15.75%. On average, research analysts expect that Masimo Co. will post 3.46 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in MASI. BlackRock Inc. lifted its stake in shares of Masimo by 6.2% during the 3rd quarter. BlackRock Inc. now owns 7,898,232 shares of the medical equipment provider’s stock worth $1,864,456,000 after buying an additional 458,222 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Masimo by 2.9% during the 3rd quarter. Victory Capital Management Inc. now owns 772,181 shares of the medical equipment provider’s stock worth $182,281,000 after buying an additional 21,982 shares during the last quarter. Champlain Investment Partners LLC lifted its stake in shares of Masimo by 2.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 728,990 shares of the medical equipment provider’s stock worth $172,085,000 after buying an additional 19,090 shares during the last quarter. Neuberger Berman Group LLC lifted its stake in shares of Masimo by 14.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 718,414 shares of the medical equipment provider’s stock worth $169,426,000 after buying an additional 90,936 shares during the last quarter. Finally, California Public Employees Retirement System lifted its stake in shares of Masimo by 291.2% during the 3rd quarter. California Public Employees Retirement System now owns 422,976 shares of the medical equipment provider’s stock worth $99,848,000 after buying an additional 314,843 shares during the last quarter. Hedge funds and other institutional investors own 78.75% of the company’s stock.

MASI has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Masimo from a “buy” rating to a “hold” rating and set a $258.00 target price for the company. in a research note on Thursday, October 8th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Tuesday, October 6th. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 6th. Raymond James increased their price objective on shares of Masimo from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Finally, Stifel Nicolaus increased their price objective on shares of Masimo from $255.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $256.43.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also: Quiet Period Expirations

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.